Vitamin B Effects on Cognitive Performance Uncertain
By HospiMedica International staff writers Posted on 26 Nov 2014 |
A new study suggests that vitamin B12 and folate supplements may not actually reduce the risk of memory and thinking problems.
Researchers at Wageningen University (The Netherlands) conducted a double-blind, randomized, placebo-controlled trial to investigate the effects of two-year folic acid and vitamin B12 supplementation on the cognitive performance of elderly people with elevated homocysteine (Hcy) levels, a potential modifiable dementia risk factor. The study included 2,919 elderly participants (65 years and older), who received a daily tablet with 400 µg folic acid and 500 µg vitamin B12, or placebo; both tablets contained 15 µg vitamin D3. Global cognitive functioning was assessed by memory and thinking skills tests at the beginning and end of the study.
The results showed that while mean Hcy concentrations decreased by 5.0 µmol/L in the vitamin B12 group and 1.3 µmol/L in the placebo group, cognitive domain scores did not differ over time between the two groups. The researchers added that while it is possible that vitamin B12 and folate supplements could slightly slow the rate of decline of global cognition, the small difference may be attributable to chance alone. The study was published on November 12, 2014, in Neurology.
“Since homocysteine levels can be lowered with folic acid and vitamin B12 supplements, the hope has been that taking these vitamins could also reduce the risk of memory loss and Alzheimer's disease,” said lead author Rosalie Dhonukshe-Rutten, PhD. “although the homocysteine levels decreased by more in the group taking the B vitamins than in the group taking the placebo, unfortunately there was no difference between the two groups in the scores on the thinking and memory tests.”
A high level of homocysteine in the blood makes a person more prone to endothelial cell injury, which leads to inflammation in the blood vessels that could lead to ischemic injury. High Hcy is therefore a possible risk factor for coronary artery disease (CAD), thrombosis, neuropsychiatric illness, and fractures. Previous studies have also shown links between higher Hcy levels, memory loss, and Alzheimer's disease.
Related Links:
Wageningen University
Researchers at Wageningen University (The Netherlands) conducted a double-blind, randomized, placebo-controlled trial to investigate the effects of two-year folic acid and vitamin B12 supplementation on the cognitive performance of elderly people with elevated homocysteine (Hcy) levels, a potential modifiable dementia risk factor. The study included 2,919 elderly participants (65 years and older), who received a daily tablet with 400 µg folic acid and 500 µg vitamin B12, or placebo; both tablets contained 15 µg vitamin D3. Global cognitive functioning was assessed by memory and thinking skills tests at the beginning and end of the study.
The results showed that while mean Hcy concentrations decreased by 5.0 µmol/L in the vitamin B12 group and 1.3 µmol/L in the placebo group, cognitive domain scores did not differ over time between the two groups. The researchers added that while it is possible that vitamin B12 and folate supplements could slightly slow the rate of decline of global cognition, the small difference may be attributable to chance alone. The study was published on November 12, 2014, in Neurology.
“Since homocysteine levels can be lowered with folic acid and vitamin B12 supplements, the hope has been that taking these vitamins could also reduce the risk of memory loss and Alzheimer's disease,” said lead author Rosalie Dhonukshe-Rutten, PhD. “although the homocysteine levels decreased by more in the group taking the B vitamins than in the group taking the placebo, unfortunately there was no difference between the two groups in the scores on the thinking and memory tests.”
A high level of homocysteine in the blood makes a person more prone to endothelial cell injury, which leads to inflammation in the blood vessels that could lead to ischemic injury. High Hcy is therefore a possible risk factor for coronary artery disease (CAD), thrombosis, neuropsychiatric illness, and fractures. Previous studies have also shown links between higher Hcy levels, memory loss, and Alzheimer's disease.
Related Links:
Wageningen University
Latest Critical Care News
- Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients
- Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot
- One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes
- AI Can Prioritize Emergency Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure